Pharma Co. Falsely Touted Obesity Drug Results, Suit Claims

By Sydney Price · May 7, 2024, 10:22 PM EDT

Biopharmaceutical company Altimmune Inc. and three of its executives were hit with a proposed class action alleging they overstated the clinical trial results and prospects of its obesity drug and its...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

IN RE ALTIMMUNE, INC. SECURITIES LITIGATION

Case Number

8:24-cv-01315

Court

Maryland

Nature of Suit

Securities/Commodities

Date Filed

May 06, 2024